Vor Biopharma Inc. reports results for the quarter ended June 30 - Earnings Summary

Vor Biopharma

11/08/2026 14:46

Vor Biopharma Inc. VOR.OQ reported a quarterly adjusted loss of $1.16​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-43.80.  The mean expectation of nine analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from -82 cents to -62 cents per share.
Reported revenue was zero​; analysts expected zero. 
Vor Biopharma Inc.'s reported EPS for the quarter was a loss of $1.16​.
The company reported a quarterly loss of $62.81 million.
Vor Biopharma Inc. shares had risen by 26.9% this quarter and gained 78.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 18.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Vor Biopharma Inc. is $40.00, about 41.6% above its last closing price of $23.37
This summary was machine generated from LSEG data August 11 at 01:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.70
-1.16
Missed
Mar. 31 2026 
-0.78
-5.11
Missed
Dec. 31 2025 
-1.68
25.84
Beat
Sep. 30 2025 
-3.25
-3.33
Missed